Scientific Advisory Board
Paul Parren, PhD
Prof. Paul W.H.I. Parren is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. He holds a PhD in molecular immunology from the University of Amsterdam (1992) and was an Associate Professor at The Scripps Research Institute. He led research and preclinical development at Genmab, He is a tenured Professor of Molecular Immunology at the Leiden University Medical Center. In 2018, he joined LAVA Therapeutics, as its Executive Vice President and Head of R&D. He also provides drug development, patent and investment advice as an independent consultant from his company Sparring Bioconsult. He is currently the chair of the Board of Directors for The Antibody Society.
Peter Ho, MD, PhD
Dr. Ho’s career has focused on cancer drug discovery and development. He previously served as Chief Medical Officer at Boston Pharmaceuticals and Epizyme Inc. Prior, he was Co-Founder and President of BeiGene Ltd. located in Beijing, China. His prior leadership roles include serving as Senior VP of oncology discovery at GlaxoSmithKline and VP of oncology development at Johnson & Johnson. He currently serves as Adjunct Associate Professor at the University of North Carolina’s Eshelman School of Pharmacy, a Scientific Advisory Board Member for Accent Therapeutics, and on the Board of Directors for Aravive Inc. and Celeris Therapeutics.
Robert Kramer, PhD
Tao Dong, DPhil
Dr. Robert Kramer has over 30 years of expertise in the oncology research industry including serving as the Vice President of Oncology Research & Development at BMS and Vice President and Global Head of Oncology Discovery at Johnson and Johnson. Dr. Kramer is currently Chief Scientific Officer of Portage Biotech. In addition, Dr. Kramer has held positions at Wyeth as the Director of Oncology-Immunology Research and as an Assistant Professor at Harvard Medical School.
Dr. Tao Dong has expertise the immunology field, more specifically in tumor-specific cytotoxic T-cells. She gained her DPhil in Immunology from Trinity College at Oxford University and the Nuffield Department of Medicine. Continuing as a postdoctoral researcher at Oxford, her research expanded to include the study of the Influenza virus. In 2010, she started her own research group, the Human T cell responses against Viruses & Cancer group. Dr. Dong is currently serving as Professor of Immunology at Oxford University and has served as the Director for Oxford-CAMS Joint International Centre for Translational Immunology and Director of CAMS Oxford Institute. In addition, Dr. Dong has served as the Head of the Anti-cancer/Anti-viral cytotoxic T cell Laboratory at Oxford University.